CDNA vs MEDP
CareDx, Inc vs Medpace — AI-powered side-by-side comparison
| Metric | CDNA | MEDP |
|---|
| AI Score |
67
|
67
|
| Price |
$45.31
|
$578.86
|
| P/E Ratio |
21.06×
|
33.27×
|
| ROE |
-7.0%
|
98.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
70.6%
|
28.8%
|
| Debt / Equity |
0.05×
|
0.28×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
57.4
|
46.4
|
| Beta |
2.419
|
1.151
|
| Expected Upside |
—
|
+7.7%
|
AI Committee View
Current Innellis committee reasoning for CDNA versus MEDP.
The committee scores are tied.
CDNA and MEDP both score 67/100.
CDNA Committee View
83% agreement
6 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is bollinger bandwidth of 45.6% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 32.8% shows genuine earnings power backing the valuation — Value
- Revenue growing 34.4% YoY -- genuine top-line momentum — Growth
- EPS growing 227.0% YoY — Growth
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 81 -- overbought on the larger timeframe too — Technical
MEDP Committee View
67% agreement
6 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is p/e of 33.1 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 110.1% shows genuine earnings power backing the valuation — Value
- EPS growing 26.8% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 33.1 is moderate-to-rich — Value
- Price-to-book of 34.5x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical